Contract Services
Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site
Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...
July 01, 2026 | News
Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...
June 29, 2026 | Analysis
Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires
For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...
June 25, 2026 | Analysis
WuXi Biologics Achieves First GMP Production at Shanghai MFG17, Expanding Global Biologics Manufacturing Capacity
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance f...
June 25, 2026 | News
Avance Clinical Expands APAC And China Operations To Accelerate Global Biotech Trials
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pacif...
June 22, 2026 | News
Pelago Bioscience Acquires RG Discovery to Create Integrated Chemistry-to-Biology Drug Discovery Platform
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement as...
June 17, 2026 | News
Chime Biologics Expands Manufacturing Capacity With New GMP-2 Facility And AI Powered Megafactory Vision
Chime Biologics’ manufacturing expansion builds on a decade of collaboration enabled by Cytiva’s modular manufacturing platform ...
June 10, 2026 | News
WuXi Biologics Completes Topping Out of Singapore Drug Product Facility
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the toppi...
June 08, 2026 | News
Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia
In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...
June 02, 2026 | Analysis
WuXi Vaccines Secures Second ANVISA GMP Certification To Accelerate Brazil Dengue Vaccine Manufacturing
WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced that...
May 27, 2026 | News
Thermo Fisher Scientific Expands PPD Laboratory Services Network With New Bioanalytical Facility In Sweden
The state-of-the-art facility enhances support for complex modalities across all phases of drug development Key facts Thermo Fisher opens new bioa...
May 19, 2026 | News
LOTTE Biologics Expands Strategic Partnership With Ottimo Pharma To Advance OTP 01 Commercial Readiness
LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developi...
May 19, 2026 | News
VectorBuilder Secures European Patent For MiniVec Plasmid System Advancing Genetic Medicine Development
Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines VectorBuilder, a global leader in ...
May 06, 2026 | News
WuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report
Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing gov...
May 01, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
